C‐peptide antioxidant adaptive pathways in β cells and diabetes

In this review, we present findings that support autocrine cell protection by C‐peptide in the context of clinical studies of type 1 diabetes (T1D), which universally measure C‐peptide serum levels as a surrogate for β cell functional mass. Over the last decade, evidence has accumulated that supports models in which C‐peptide, cosecreted with insulin by pancreatic β cells, acts on peripheral targets including the vascular endothelium to reduce oxidative stress and apoptosis subsequent to exposure to diabetic insults. In parallel, as assays have become more sensitive, C‐peptide has been detected in the circulation of most subjects with T1D where higher C‐peptide levels are associated with fewer and slower development of diabetic microvascular complications, consistent with antioxidant protection by C‐peptide. Clinical trials investigating C‐peptide‐replacement therapy effects have demonstrated amelioration of T1D nephropathy and neuropathy. Recently, the antioxidant action of C‐peptide was extended to the β cells secreting it, that is an autocrine mechanism. Autocrine protection has major implications for the treatment of diabetes because the more C‐peptide secreted, the more protection provided to the same β cells resulting in a slower decay in β cell functional mass over the time course of disease. Why β cells evolved to cosecrete an antioxidant C‐peptide hormone together with the glycaemia‐lowering insulin hormone is explored in the context of proposed evolutionary advantages of physiologically transient oxidative stress and insulin resistance as an adaptation for survival through times of fuel scarcity. The importance of recognizing autocrine C‐peptide protection of functional β cell mass in observational clinical studies, and its therapeutic implications in interventional C‐peptide‐replacement studies, will be discussed.